Human medicines European public assessment report (EPAR): Riltrava Aerosphere, formoterol fumarate dihydrate,glycopyrronium,budesonide, Date of authorisation: 06/01/2022, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Rystiggo, rozanolixizumab, Date of authorisation: 05/01/2024, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Aucatzyl, obecabtagene autoleucel, Date of authorisation: 17/07/2025, Status: Authorised

Human medicines European public assessment report (EPAR): Ultomiris, ravulizumab, Date of authorisation: 02/07/2019, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Invanz, ertapenem, Date of authorisation: 18/04/2002, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR): Capvaxive, pneumococcal polysaccharide conjugate vaccine (21-valent), Date of authorisation: 24/03/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): ProQuad, measles, mumps, rubella and varicella vaccine (live), Date of authorisation: 05/04/2006, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR): M-M-RVaxPro, measles, mumps and rubella vaccine (live), Date of authorisation: 05/05/2006, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR): Venclyxto, venetoclax, Date of authorisation: 04/12/2016, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Shingrix, herpes zoster vaccine (recombinant, adjuvanted), Date of authorisation: 21/03/2018, Revision: 13, Status: Authorised